WARNING: FETAL RISK
Women of childbearing potential should have a serum pregnancy test prior to administration of VIBATIV
Avoid use of VIBATIV during pregnancy unless the potential benefit to the patient outweighs the potential risk to the fetus
Adverse developmental outcomes observed in 3 animal species at clinically relevant doses raise concerns about potential adverse developmental outcomes in humans [see Warnings and Precautions Use in Specific Populations]
VIBATIV contains telavancin hydrochloride, a lipoglycopeptide antibacterial that is a synthetic derivative of vancomycin.
VIBATIV is a lipoglycopeptide antibacterial indicated for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria.
Published Studies Related to Vibativ (Telavancin)
Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. [2011.01.01]
BACKGROUND: Telavancin is a lipoglycopeptide bactericidal against gram-positive pathogens... CONCLUSIONS: The primary end point of the studies was met, indicating that telavancin is noninferior to vancomycin on the basis of clinical response in the treatment of HAP due to gram-positive pathogens.
Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive
pathogens... CONCLUSIONS: The primary end point of the studies was met, indicating that
ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections. [2010.12]
Telavancin is an injectable lipoglycopeptide that is bactericidal in vitro against staphylococci, streptococci and vancomycin-susceptible enterococci. Telavancin inhibits bacterial cell wall synthesis by interfering with the synthesis of peptidoglycan, and binds to the bacterial membrane and disrupts membrane barrier function...
Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects. [2010.02]
CONCLUSION: These pharmacokinetic data show that intravenous telavancin administered at the intended therapeutic dose does not affect the pharmacokinetics of intravenous midazolam. The results indicate that telavancin is unlikely to inhibit hepatic CYP3A activity to a clinically meaningful extent.
Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants. [2009.07]
This randomized crossover study in healthy participants assessed pharmacokinetic interactions between telavancin, aztreonam, and piperacillin/tazobactam... Administration of aztreonam or piperacillin/tazobactam with telavancin had no clinically significant effect on the pharmacokinetic disposition of any of these drugs.
Clinical Trials Related to Vibativ (Telavancin)
VIBATIV Pregnancy Registry [Recruiting]
The purpose of this registry is to evaluate the outcome of pregnancy in women exposed to
VIBATIV at any time during pregnancy. There are no mandated physician visits for the
Safety and Efficacy of Telavancin [Recruiting]
The goal of this clinical research study is to learn if Vibativ (telavancin) can help to
control blood stream infections (BSIs). The safety of this treatment will also be studied.
Evaluate the clinical efficacy and safety of Telavancin given for treatment of gram positive
bacteremia in cancer patients (including neutropenics).
Reports of Suspected Vibativ (Telavancin) Side Effects
Blood Glucose Increased (3),
Muscle Spasms (2),
Electrocardiogram QT Prolonged (1),
Disease Progression (1),
Death (1), more >>
Page last updated: 2013-02-10